These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 31669562

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study.
    Gouvêa de Lima A, Villar RC, de Castro G, Antequera R, Gil E, Rosalmeida MC, Federico MH, Snitcovsky IM.
    Int J Radiat Oncol Biol Phys; 2012 Jan 01; 82(1):270-5. PubMed ID: 21163585
    [Abstract] [Full Text] [Related]

  • 3. Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck.
    Allison RR, Ambrad AA, Arshoun Y, Carmel RJ, Ciuba DF, Feldman E, Finkelstein SE, Gandhavadi R, Heron DE, Lane SC, Longo JM, Meakin C, Papadopoulos D, Pruitt DE, Steinbrenner LM, Taylor MA, Wisbeck WM, Yuh GE, Nowotnik DP, Sonis ST.
    Cancer; 2014 May 01; 120(9):1433-40. PubMed ID: 24877167
    [Abstract] [Full Text] [Related]

  • 4. Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment.
    Lozano A, Marruecos J, Rubió J, Farré N, Gómez-Millán J, Morera R, Planas I, Lanzuela M, Vázquez-Masedo MG, Cascallar L, Giralt J, Escames G, Valentí V, Grima P, Bosser R, Tarragó C, Mesía R.
    Clin Transl Oncol; 2021 Sep 01; 23(9):1801-1810. PubMed ID: 33738704
    [Abstract] [Full Text] [Related]

  • 5. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.
    Le QT, Kim HE, Schneider CJ, Muraközy G, Skladowski K, Reinisch S, Chen Y, Hickey M, Mo M, Chen MG, Berger D, Lizambri R, Henke M.
    J Clin Oncol; 2011 Jul 10; 29(20):2808-14. PubMed ID: 21670453
    [Abstract] [Full Text] [Related]

  • 6. Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.
    Anderson CM, Lee CM, Saunders DP, Curtis A, Dunlap N, Nangia C, Lee AS, Gordon SM, Kovoor P, Arevalo-Araujo R, Bar-Ad V, Peddada A, Colvett K, Miller D, Jain AK, Wheeler J, Blakaj D, Bonomi M, Agarwala SS, Garg M, Worden F, Holmlund J, Brill JM, Downs M, Sonis ST, Katz S, Buatti JM.
    J Clin Oncol; 2019 Dec 01; 37(34):3256-3265. PubMed ID: 31618127
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy--a randomized controlled trial.
    Gautam AP, Fernandes DJ, Vidyasagar MS, Maiya AG, Nigudgi S.
    Support Care Cancer; 2013 May 01; 21(5):1421-8. PubMed ID: 23224689
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the Systemic and Local Pharmacokinetics of Clonidine Mucoadhesive Buccal Tablets with Reference Clonidine Oral Tablets in Healthy Volunteers: An Open-Label Randomised Cross-Over Trial.
    Vasseur B, Dufour A, Houdas L, Goodwin H, Harries K, Emul NY, Hutchings S.
    Adv Ther; 2017 Aug 01; 34(8):2022-2032. PubMed ID: 28726169
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer.
    Yokota T, Hamauchi S, Yoshida Y, Yurikusa T, Suzuki M, Yamashita A, Ogawa H, Onoe T, Mori K, Onitsuka T.
    Support Care Cancer; 2018 Sep 01; 26(9):3241-3248. PubMed ID: 29627862
    [Abstract] [Full Text] [Related]

  • 11. Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
    Yen SH, Wang LW, Lin YH, Jen YM, Chung YL.
    Int J Radiat Oncol Biol Phys; 2012 Mar 15; 82(4):1463-70. PubMed ID: 21840136
    [Abstract] [Full Text] [Related]

  • 12. The effectiveness of Zataria extract mouthwash for the management of radiation-induced oral mucositis in patients: a randomized placebo-controlled double-blind study.
    Aghamohammadi A, Moslemi D, Akbari J, Ghasemi A, Azadbakht M, Asgharpour A, Hosseinimehr SJ.
    Clin Oral Investig; 2018 Jul 15; 22(6):2263-2272. PubMed ID: 29313134
    [Abstract] [Full Text] [Related]

  • 13. Confounding factors associated with oral mucositis assessment in patients receiving chemoradiotherapy for head and neck cancer.
    Chung YL, Pui NNM.
    Support Care Cancer; 2017 Sep 15; 25(9):2743-2751. PubMed ID: 28353040
    [Abstract] [Full Text] [Related]

  • 14. Effect of photobiomodulation on the severity of oral mucositis and molecular changes in head and neck cancer patients undergoing radiotherapy: a study protocol for a cost-effectiveness randomized clinical trial.
    Martins AFL, Nogueira TE, Morais MO, Oton-Leite AF, Valadares MC, Batista AC, Freitas NMA, Leles CR, Mendonça EF.
    Trials; 2019 Feb 01; 20(1):97. PubMed ID: 30709370
    [Abstract] [Full Text] [Related]

  • 15. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial.
    Henke M, Alfonsi M, Foa P, Giralt J, Bardet E, Cerezo L, Salzwimmer M, Lizambri R, Emmerson L, Chen MG, Berger D.
    J Clin Oncol; 2011 Jul 10; 29(20):2815-20. PubMed ID: 21670447
    [Abstract] [Full Text] [Related]

  • 16. Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy.
    Rastogi M, Khurana R, Revannasiddaiah S, Jaiswal I, Nanda SS, Gupta P, Chufal KS, Bhatt ML.
    Support Care Cancer; 2017 May 10; 25(5):1439-1443. PubMed ID: 27987094
    [Abstract] [Full Text] [Related]

  • 17. Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation.
    Antunes HS, Herchenhorn D, Small IA, Araújo CM, Viégas CM, Cabral E, Rampini MP, Rodrigues PC, Silva TG, Ferreira EM, Dias FL, Ferreira CG.
    Radiother Oncol; 2013 Nov 10; 109(2):297-302. PubMed ID: 24044799
    [Abstract] [Full Text] [Related]

  • 18. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy.
    Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, Pajak TF, Fleming TR, Henke M, Bourhis J, Rosenthal DI, Junor E, Cmelak A, Sheehan F, Pulliam J, Devitt-Risse P, Fuchs H, Chambers M, O'Sullivan B, Ang KK.
    Int J Radiat Oncol Biol Phys; 2004 Mar 01; 58(3):674-81. PubMed ID: 14967419
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
    Yokota T, Ogawa T, Takahashi S, Okami K, Fujii T, Tanaka K, Iwae S, Ota I, Ueda T, Monden N, Matsuura K, Kojima H, Ueda S, Sasaki K, Fujimoto Y, Hasegawa Y, Beppu T, Nishimori H, Hirano S, Naka Y, Matsushima Y, Fujii M, Tahara M.
    BMC Cancer; 2017 May 05; 17(1):314. PubMed ID: 28476132
    [Abstract] [Full Text] [Related]

  • 20. Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer.
    Marucci L, Farneti A, Di Ridolfi P, Pinnaro P, Pellini R, Giannarelli D, Vici P, Conte M, Landoni V, Sanguineti G.
    Head Neck; 2017 Sep 05; 39(9):1761-1769. PubMed ID: 28560780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.